Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Apical Hypertrophic Cardiomyopathy in Middle-aged Male with Chest Pain
Author(s): Kannu Bansal , Ramses Thabet Nasif Added: 1 year ago

Heart Failure
Added: 3 months ago Source:  Radcliffe Cardiology
A novel cardiac myosin agonist, danicamtiv, has shown favourable safety and efficacy signals in patients with dilated cardiomyopathy (DCM), particularly in those with specific genetic variants, according to results from a phase 2a open-label trial.¹ Precision therapies for DCM are currently lacking, despite its diverse clinical manifestations often linked to underlying genetic causes.²Danicamtiv… View more

Imaging & Diagnostics

Inherited and Congenital Cardiac Conditions
New Challenges in Heart Failure: An Expert Assessment of How Real-World Observations Are Changing Our Practice
Author(s): Giuseppe Rosano , John R Teerlink , Koichiro Kinugawa Added: 11 months ago
This comprehensive video series has been designed to enhance your understanding of heart failure (HF) management. Through expert discussions, we explore the real-world adoption of novel guideline-directed medical therapies (GDMTs) and their impact on patient care. We also delve into the benefits of natriuretic peptide (NP) testing, highlighting how it aids in more accurate and rapid diagnosis,… View more

Heart Failure
The Heart of Medicine: Healing Beyond Numbers
Author(s): Rawan Amir Added: 12 months ago

Heart Failure
BMI Affects NT-proBNP Risk Stratification in HFpEF
Added: 5 months ago Source:  Radcliffe Cardiology
Natriuretic peptides are key biomarkers used to risk-stratify patients with heart failure (HF), but current guideline thresholds do not typically account for body mass index (BMI).¹ A new pooled analysis suggests that these fixed thresholds may underestimate risk in patients with HF and higher BMI, questioning the one-size-fits-all approach.²This study was a participant-level pooled analysis of… View more

Cardiovascular Renal Metabolic

Electrophysiology & Arrhythmia
AHA 2025 Highlights: New Insights on Icosapent Ethyl
Author(s): Deepak L Bhatt , Payal Kohli Added: 4 months ago
Filmed onsite at the AHA 2025 congress, leading specialists Dr Payal Kohli and Dr Deepak Bhatt explore the evolving landscape of triglyceride-lowering therapy in cardiovascular disease.They review new REDUCE-IT sub-analysis data on icosapent ethyl efficacy by aspirin use, examine updated ESC guideline recommendations and discuss how eicosapentaenoic acid (EPA) delivers cardioprotective benefits… View more

Heart Failure

Prevention & Chronic Conditions
Job title: Section Editor - Aortic, Vascular & Endovascular Review, Radcliffe Vascular
Dr Andrew Choong is a consultant vascular, endovascular and aortic surgeon at the National University Heart Centre, Singapore and an Assistant Professor in the Department of Surgery of the Yong Loo Lin School of Medicine, National University of Singapore. Dr Choong graduated from the Imperial College School of Medicine at St Mary’s, London, UK in 2003. He further developed his endovascular… View more
FDA Approves Finerenone for Heart Failure with LVEF ≥40%
Added: 7 months ago Source:  Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The… View more

Cardiovascular Renal Metabolic

Guidelines & Statements
Ep 139: The Genetic Revolution in HCM: Mapping Family Risk to Targeted Treatment
Added: 8 months ago
In this essential episode of Parallax, Dr Ankur Kalra is joined by Dr Carolyn Ho, Professor of Medicine at Harvard Medical School and Medical Director of the Cardiovascular Genetics Program at Brigham and Women's Hospital, for a comprehensive discussion on how genetic testing is reshaping hypertrophic cardiomyopathy management.The conversation explores the VANISH HCM trial results, which showed… View more

Demographic

Heart Failure
PAP Therapies for HF: What Do the Trials Tell Us?
Author(s): Jan Pec , Michael Arzt Added: 4 months ago

Guidelines & Statements

Heart Failure